Results 1 to 10 of about 36,204 (201)

Clozapine-induced agranulocytosis [PDF]

Annals of Hematology, 2020
AbstractWider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant schizophrenia, with mandatory blood count monitoring for the duration of treatment.
Aleksandar Mijovic, James H. MacCabe
openaire   +4 more sources

A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

CNS Drugs, 2022
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be treated as soon as possible to improve their chances of achieving remission ...
C. Correll, O. Agid, B. Crespo-Facorro, A. de Bartolomeis, A. Fagiolini, N. Seppälä, O. Howes   +6 more
semanticscholar   +1 more source

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.

Pharmacopsychiatry, 2021
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it ...
J. de Leon, G. Schoretsanitis, R. L. Smith, E. Molden, Anssi Solismaa, N. Seppälä, M. Kopeček, Patrik Švancer, I. Olmos, Carina Ricciardi, C. Iglesias-Garcia, Ana Iglesias-Alonso, E. Spina, Can-Jun Ruan, Chuanyue Wang, Gang Wang, Yi-Lang Tang, Shih-ku Lin, H. Lane, Y. S. Kim, Se Hyun Kim, A. Rajkumar, D. González-Esquivel, H. Jung-Cook, T. Baptista, C. Rohde, J. Nielsen, H. Verdoux, C. Quiles, E. Sanz, Carlos De Las Cuevas, D. Cohen, P. Schulte, A. Ertugrul, A. E. A. Yagcioglu, N. Chopra, Betsy McCollum, Charles Shelton, Robert O. Cotes, Arun R Kaithi, J. Kane, S. Farooq, C. Ng, John Bilbily, C. Hiemke, C. López-Jaramillo, Ian R. McGrane, F. Lana, C. Eap, M. Arrojo-Romero, F. Radulescu, E. Seifritz, S. Every-Palmer, C. Bousman, E. Bebawi, Rahul Bhattacharya, D. Kelly, Yuji Otsuka, J. Lazary, Rafael Torres, Agustín Yécora, Mariano Motuca, S. Chan, M. Zolezzi, S. Ouanes, D. D. Berardis, S. Grover, R. Procyshyn, Richard A Adebayo, O. Kirilochev, A. Soloviev, K. Fountoulakis, A. Wilkowska, W. Cubała, Muhammad Ayub, Alzira Silva, R. Bonelli, J. M. Villagrán-Moreno, B. Crespo-Facorro, H. Temmingh, E. Decloedt, Maria R Pedro, H. Takeuchi, Masaru Tsukahara, G. Gründer, M. Šagud, A. Čelofiga, D. Ristic, Bruno B Ortiz, H. Elkis, A. P. Pacheco Palha, A. Llerena, E. Fernandez-Egea, D. Siskind, Abraham Weizman, R. Masmoudi, S. Saffian, J. Leung, P. Buckley, S. Marder, L. Citrome, O. Freudenreich, C. Correll, D. Müller   +103 more
semanticscholar   +1 more source

Reflections on the Complex History of the Concept of Clozapine-Induced Inflammation during Titration.

Psychiatria Danubina, 2022
Clozapine was synthesized in 1958. The Food and Drug Administration approved it in 1989 when comprehensive pharmacokinetic studies were not required and it was not known that clozapine was metabolized by the cytochrome P450 1A2 (CYP1A2).
Jose de Leon
semanticscholar   +1 more source

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis

Schizophrenia, 2022
The wider use of clozapine is limited by the risk of agranulocytosis and the associated requirement for monitoring of neutrophil counts. We searched local electronic patient records for cases of agranulocytosis occurring during clozapine treatment during
David Taylor, Kalliopi A. Vallianatou, Eromona Whiskey, O. Dzahini, J. MacCabe   +4 more
semanticscholar   +1 more source

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review

Translational Psychiatry, 2021
A recent increase in the literature regarding the evidence base for clozapine has made it increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we aimed at elucidating the state-of-the-art for clozapine with regard to
E. Wagner, S. Siafis, P. Fernando, P. Falkai, W. Honer, A. Röh, D. Siskind, S. Leucht, A. Hasan   +8 more
semanticscholar   +1 more source

A Focused Review of the Metabolic Side-Effects of Clozapine

Frontiers in Endocrinology, 2021
The second generation antipsychotic drug clozapine represents the most effective pharmacotherapy for treatment-resistant psychosis. It is also associated with low rates of extrapyramidal symptoms and hyperprolactinemia compared to other antipsychotic ...
Jessica W. Y. Yuen, David D. Kim, R. Procyshyn, W. Panenka, W. Honer, A. Barr   +5 more
semanticscholar   +1 more source

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia

Schizophrenia bulletin, 2021
It has been suggested that the antipsychotic clozapine may modulate brain glutamate, and that this effect could contribute to its efficacy in treatment-resistant schizophrenia (TRS).
Grant McQueen, K. Sendt, A. Gillespie, A. Avila, J. Lally, Kalliopi A. Vallianatou, N. Chang, D. Ferreira, F. Borgan, O. Howes, G. Barker, D. Lythgoe, J. Stone, P. McGuire, J. MacCabe, A. Egerton   +15 more
semanticscholar   +1 more source

Clozapine levels as a predictor for therapeutic response: A systematic review and meta‐analysis

Acta Psychiatrica Scandinavica, 2021
Clozapine levels may be a more useful predictor of therapeutic response than the dose, given the variability in clozapine metabolism between individuals.
D. Siskind, Meghna Sharma, M. Pawar, E. Pearson, E. Wagner, N. Warren, S. Kisely   +6 more
semanticscholar   +1 more source

A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology

Psychotherapy and Psychosomatics, 2020
Using Richardson and Davidson’s model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who
J. de Leon, Can-Jun Ruan, G. Schoretsanitis, C. de Las Cuevas   +3 more
semanticscholar   +1 more source